The CFDA issued four documents in two days. What does this mean? How is the reduction of the backlog of drug registration applications going? Is there any new progress of consistency evaluation? Will the Marketing Authorization Holder (MAH) pilot program end earlier? How will the drug R&D ecosystem be purified? What are the main work goals for the next phase? All these questions will be answered by CFDA Vice Minister Sun Xianze at the 2017 China Healthcare Summit of Entrepreneurs, Scientists and Investors.
(1) Building 30 overseas TCM centers in partnership with countries along the Belt and Road; (2) building 50 TCM cooperation demonstration bases in China; (3) working with countries along the Belt and Road to develop 20 international standards and norms for TCM; and (4) supporting the international registration of 100 TCM products.